According to Laboratory Corporation of America (LabCorp), in a recent study of high risk and average risk subjects, this blood test, using six biomarkers and research conducted at Yale University School of Medicine, was shown to discriminate between disease-free women and ovarian cancer patients (stage I-IV) with high specificity (99.4%) and sensitivity (95.3%).
Additional studies performed at Yale University School of Medicine demonstrate comparable findings, the company said.
Myla Lai-Goldman, executive vice president and chief medical officer of LabCorp, said: “OvaSure is a significant addition to LabCorp’s family of proteomic tests, and a major component of LabCorp’s strategy to bring the latest in diagnostic technology to women’s healthcare.”